Difference between revisions of "Team:Sydney Australia/Patent Law"

Line 230: Line 230:
 
bioactivity<o:p></o:p></span></p>
 
bioactivity<o:p></o:p></span></p>
  
−
<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Patent No: US 9458,220 B2<o:p></o:p></span></p>
+
<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Patent No: <b style="mso-bidi-font-weight:
 +
normal">US 9458,220 B2<o:p></o:p></b></span></p>
  
 
<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">October <span class="GramE">4<sup>th</sup></span>
 
<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">October <span class="GramE">4<sup>th</sup></span>
 
2016<o:p></o:p></span></p>
 
2016<o:p></o:p></span></p>
  
−
<p class="MsoNormal"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+
<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
  
−
<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
+
<table class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="97%" style="width:97.26%;margin-left:21.05pt;border-collapse:collapse;border:none;
−
mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt">
+
mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:1184;mso-padding-alt:
 +
0cm 5.4pt 0cm 5.4pt">
 
  <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:16.25pt">
 
  <tbody><tr style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:16.25pt">
−
   <td width="49%" style="width:49.92%;border:solid windowtext 1.0pt;mso-border-alt:
+
   <td width="50%" style="width:50.94%;border:solid windowtext 1.0pt;mso-border-alt:
−
   solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
+
   solid windowtext .5pt;background:#FFF2CC;mso-background-themecolor:accent4;
−
   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand"><o:p>&nbsp;</o:p></span></p>
+
  mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
−
   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand">CLAIM<br style="mso-special-character:
+
   <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:15.0pt;
−
  line-break">
+
  font-family:Quicksand"><o:p>&nbsp;</o:p></span></b></p>
 +
   <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:15.0pt;
 +
  font-family:Quicksand">CLAIM<br style="mso-special-character:line-break">
 
   <!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
 
   <!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
−
   <!--[endif]--></span><span lang="EN-AU" style="font-size:11.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+
   <!--[endif]--></span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:11.0pt;font-family:Quicksand"><o:p></o:p></span></b></p>
 
   </td>
 
   </td>
−
   <td width="42%" style="width:42.66%;border:solid windowtext 1.0pt;border-left:
+
   <td width="43%" style="width:43.5%;border:solid windowtext 1.0pt;border-left:
 
   none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
−
   padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
+
   background:#FFF2CC;mso-background-themecolor:accent4;mso-background-themetint:
−
   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand"><br>
+
  51;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
 +
   <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:15.0pt;
 +
  font-family:Quicksand"><br>
 
   COMPARISON WITH OUR SEQUENCE<br style="mso-special-character:line-break">
 
   COMPARISON WITH OUR SEQUENCE<br style="mso-special-character:line-break">
 
   <!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
 
   <!--[if !supportLineBreakNewLine]--><br style="mso-special-character:line-break">
−
   <!--[endif]--></span><span lang="EN-AU" style="font-size:11.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+
   <!--[endif]--></span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:11.0pt;font-family:Quicksand"><o:p></o:p></span></b></p>
 
   </td>
 
   </td>
−
   <td width="7%" style="width:7.42%;border:solid windowtext 1.0pt;border-left:
+
   <td width="5%" style="width:5.58%;border:solid windowtext 1.0pt;border-left:
 
   none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
−
   padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
+
   background:#FFF2CC;mso-background-themecolor:accent4;mso-background-themetint:
−
   <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand">Y/N</span><span lang="EN-AU" style="font-size:11.0pt;font-family:Quicksand"><o:p></o:p></span></p>
+
  51;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
 +
   <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:15.0pt;
 +
  font-family:Quicksand">Y/N</span></b><b style="mso-bidi-font-weight:normal"><span lang="EN-AU" style="font-size:11.0pt;font-family:Quicksand"><o:p></o:p></span></b></p>
 
   </td>
 
   </td>
 
  </tr>
 
  </tr>
 
  <tr style="mso-yfti-irow:1;height:70.1pt">
 
  <tr style="mso-yfti-irow:1;height:70.1pt">
−
   <td width="49%" style="width:49.92%;border:solid windowtext 1.0pt;border-top:
+
   <td width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   padding:0cm 5.4pt 0cm 5.4pt;height:70.1pt">
 
   padding:0cm 5.4pt 0cm 5.4pt;height:70.1pt">
Line 272: Line 280:
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   color:black">A single chain insulin agonist analogue with stricture of B-LM-A
 
   color:black">A single chain insulin agonist analogue with stricture of B-LM-A
−
   <span class="GramE">wherein</span>&nbsp;B represents an insulin B chain
+
   <span class="GramE">wherein</span>&nbsp;B represents an insulin B chain comprising
−
   comprising the sequence R<sub>22</sub>X<sub>25</sub>LCGX<sub>29</sub></span><sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Helvetica;mso-fareast-font-family:
+
   the sequence R<sub>22</sub>X<sub>25</sub>LCGX<sub>29</sub></span><sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
 
   Helvetica;mso-bidi-font-family:Helvetica;color:black">…</span></sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Helvetica;mso-bidi-font-family:Helvetica;color:black">…</span></sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Times;color:black"> <sub>&nbsp;</sub>and A represents an insulin A chain
 
   Times;color:black"> <sub>&nbsp;</sub>and A represents an insulin A chain
Line 279: Line 287:
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
−
   color:black">GIVX<sub>4</sub>X<sub>5</sub>CCX<sub>8</sub></span><sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Helvetica;mso-fareast-font-family:
+
   color:black">GIVX<sub>4</sub>X<sub>5</sub>CCX<sub>8</sub></span><sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
 
   Helvetica;mso-bidi-font-family:Helvetica;color:black">…</span></sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Helvetica;mso-bidi-font-family:Helvetica;color:black">…</span></sub><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Times;color:black">-R<sub>13</sub> <br style="mso-special-character:line-break">
 
   Times;color:black">-R<sub>13</sub> <br style="mso-special-character:line-break">
Line 285: Line 293:
 
   <!--[endif]--><o:p></o:p></span></p>
 
   <!--[endif]--><o:p></o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="42%" style="width:42.66%;border-top:none;border-left:none;
+
   <td width="43%" style="width:43.5%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
Line 301: Line 309:
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="7%" style="width:7.42%;border-top:none;border-left:none;
+
   <td width="5%" style="width:5.58%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
−
   mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:70.1pt">
+
   mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
  height:70.1pt">
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black"><o:p>&nbsp;</o:p></span></p>
+
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black"><o:p>&nbsp;</o:p></span></p>
+
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black"><o:p>&nbsp;</o:p></span></p>
+
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   color:black">N<o:p></o:p></span></p>
 
   color:black">N<o:p></o:p></span></p>
 +
  <p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times"><o:p>&nbsp;</o:p></span></p>
 
   </td>
 
   </td>
 
  </tr>
 
  </tr>
 
  <tr style="mso-yfti-irow:2;height:36.55pt">
 
  <tr style="mso-yfti-irow:2;height:36.55pt">
−
   <td width="49%" style="width:49.92%;border:solid windowtext 1.0pt;border-top:
+
   <td width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
 
   padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
Line 355: Line 356:
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="42%" style="width:42.66%;border-top:none;border-left:none;
+
   <td width="43%" style="width:43.5%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
Line 388: Line 389:
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   color:black">B-chain </span><span lang="EN-AU" style="font-size:14.0pt;
 
   color:black">B-chain </span><span lang="EN-AU" style="font-size:14.0pt;
−
   font-family:Helvetica;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+
   font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
 
   Helvetica;color:black">–</span><span lang="EN-AU" style="font-size:14.0pt;
 
   Helvetica;color:black">–</span><span lang="EN-AU" style="font-size:14.0pt;
−
   font-family:Quicksand;mso-bidi-font-family:Times;color:black"> QR . . . RR </span><span lang="EN-AU" style="font-size:14.0pt;font-family:Helvetica;mso-fareast-font-family:
+
   font-family:Quicksand;mso-bidi-font-family:Times;color:black"> QR . . . RR </span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
 
   Helvetica;mso-bidi-font-family:Helvetica;color:black">–</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Helvetica;mso-bidi-font-family:Helvetica;color:black">–</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Times;color:black"> A-chain</span><span lang="EN-AU" style="font-size:14.0pt;
 
   Times;color:black"> A-chain</span><span lang="EN-AU" style="font-size:14.0pt;
−
   font-family:Helvetica;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+
   font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
 
   Helvetica;color:black"><o:p></o:p></span></p>
 
   Helvetica;color:black"><o:p></o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="7%" style="width:7.42%;border-top:none;border-left:none;
+
   <td width="5%" style="width:5.58%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
−
   mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt">
+
   mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
  height:36.55pt">
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black;mso-bidi-font-style:italic"><o:p>&nbsp;</o:p></span></p>
+
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black;mso-bidi-font-style:italic"><o:p>&nbsp;</o:p></span></p>
+
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black;mso-bidi-font-style:italic"><o:p>&nbsp;</o:p></span></p>
+
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black;mso-bidi-font-style:italic"><o:p>&nbsp;</o:p></span></p>
+
−
  <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
+
−
  mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
+
−
  color:black;mso-bidi-font-style:italic"><o:p>&nbsp;</o:p></span></p>
+
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
Line 421: Line 408:
 
  </tr>
 
  </tr>
 
  <tr style="mso-yfti-irow:3;height:52.55pt">
 
  <tr style="mso-yfti-irow:3;height:52.55pt">
−
   <td width="49%" style="width:49.92%;border:solid windowtext 1.0pt;border-top:
+
   <td width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   padding:0cm 5.4pt 0cm 5.4pt;height:52.55pt">
 
   padding:0cm 5.4pt 0cm 5.4pt;height:52.55pt">
Line 435: Line 422:
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="42%" style="width:42.66%;border-top:none;border-left:none;
+
   <td width="43%" style="width:43.5%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
Line 444: Line 431:
 
   amino acids.<o:p></o:p></span></p>
 
   amino acids.<o:p></o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="7%" style="width:7.42%;border-top:none;border-left:none;
+
   <td width="5%" style="width:5.58%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
−
   mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:52.55pt">
+
   mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
 +
  height:52.55pt">
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
Line 454: Line 442:
 
  </tr>
 
  </tr>
 
  <tr style="mso-yfti-irow:4;mso-yfti-lastrow:yes;height:16.25pt">
 
  <tr style="mso-yfti-irow:4;mso-yfti-lastrow:yes;height:16.25pt">
−
   <td width="49%" style="width:49.92%;border:solid windowtext 1.0pt;border-top:
+
   <td width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
 
   padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
 
   padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
Line 464: Line 452:
 
   color:black">LM represents linking moiety linking the carboxyl terminus of
 
   color:black">LM represents linking moiety linking the carboxyl terminus of
 
   the B chain to the amino terminus of <span class="GramE">the a</span> chain,
 
   the B chain to the amino terminus of <span class="GramE">the a</span> chain,
−
   wherein said linking moiety is an <span style="mso-bidi-font-weight:bold">8 amino
+
   wherein said linking moiety is an <span style="mso-bidi-font-weight:bold">8
−
   acid sequence</span> consisting of X<sub>51</sub>X<sub>52</sub>X<sub>53</sub>X<sub>54</sub>...
+
   amino acid sequence</span> consisting of X<sub>51</sub>X<sub>52</sub>X<sub>53</sub>X<sub>54</sub>...
 
   wherein X<sub>51</sub></span><span lang="EN-AU" style="font-size:14.0pt;
 
   wherein X<sub>51</sub></span><span lang="EN-AU" style="font-size:14.0pt;
−
   font-family:Helvetica;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
+
   font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
 
   Helvetica;color:black"> </span><span lang="EN-AU" style="font-size:14.0pt;
 
   Helvetica;color:black"> </span><span lang="EN-AU" style="font-size:14.0pt;
 
   font-family:Quicksand;mso-bidi-font-family:Times;color:black">is selected
 
   font-family:Quicksand;mso-bidi-font-family:Times;color:black">is selected
 
   from the group consisting of glycine, alanine, valine, leucine, isoleucine
 
   from the group consisting of glycine, alanine, valine, leucine, isoleucine
−
   and proline</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Helvetica;
+
   and proline</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;
 
   mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">…</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">…</span><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
 
   Times;color:black"><o:p></o:p></span></p>
 
   Times;color:black"><o:p></o:p></span></p>
Line 478: Line 466:
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   color:black"><o:p>&nbsp;</o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="42%" style="width:42.66%;border-top:none;border-left:none;
+
   <td width="43%" style="width:43.5%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
Line 494: Line 482:
 
   orientation) and outside the scope<o:p></o:p></span></p>
 
   orientation) and outside the scope<o:p></o:p></span></p>
 
   </td>
 
   </td>
−
   <td width="7%" style="width:7.42%;border-top:none;border-left:none;
+
   <td width="5%" style="width:5.58%;border-top:none;border-left:none;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
 
   mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
−
   mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt">
+
   mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
 +
  height:16.25pt">
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   <p class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
 
   mso-layout-grid-align:none;text-autospace:none"><span lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
Line 504: Line 493:
 
  </tr>
 
  </tr>
 
</tbody></table>
 
</tbody></table>
 +
 
</div>     
 
</div>     
 
<div class="patent_1 box">
 
<div class="patent_1 box">

Revision as of 11:53, 25 October 2017

GENERAL HEADER ON OUR PATENTS

Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Regardless, our work is for ‘research purposes’ in which an exception exists for patents under WHAT?? Testing of claims from patents are not illegal so long as we do not directly market this product which our team is not pursuing at this stage.


DIMARCHI ET AL.

Single Chain Insulin with high bioactivity

Patent No: US 9458,220 B2

October 4th 2016

 

 

CLAIM


COMPARISON WITH OUR SEQUENCE

Y/N

 

A single chain insulin agonist analogue with stricture of B-LM-A wherein B represents an insulin B chain comprising the sequence R22X25LCGX29…  and A represents an insulin A chain comprising the sequence

GIVX4X5CCX8…-R13

 

Both insulin A and B chains involve R groups which stand for modifications eg. carboxylation. As our insulin B chain does not contain any modifications (except an additional glycine at the A chain), our construct is outside the patent

 

N

 

 

Furthermore the linking moiety linking the carboxy terminus of the B chain to the amino terminus of the A chain; further wherein the linking moiety is an 8 amino acid sequence comprising of the sequence X51X52GSSSX57X58 wherein

X51 = group consisting of glycine, alanine, valine, leucine, isoleucine, isoleucine and ornithine

X52 = any amino acid other than tyrosine

X57 and X58 are independently selected form the ground consisting of arginine, lysine and ornithine

 

 

Our amino acid sequence is squarely outside the scope of 8 amino acids.

 

Even if we did fall within the claim; we do not contain the 8 amino acid sequence using both potential orientations

 

X51 is glutamine or arginine in our sequence

 

 

B-chain – QR . . . RR – A-chain

N

 

The LM also requires the sequence of GAGSSSRR or a sequence that differs from GAGSSRR by 1 or 2 amino acids

 

Our sequence is 12 amino acids long and differs by more than 4 amino acids.

N

 

LM represents linking moiety linking the carboxyl terminus of the B chain to the amino terminus of the a chain, wherein said linking moiety is an 8 amino acid sequence consisting of X51X52X53X54... wherein X51 is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine and proline…

 

Similarly, the patent claim is over an 8 amino acid sequence. Applying the same principle our;

 

X51 is glutamine or arginine (depending on orientation) and outside the scope

N

LEE ET AL.

Single Chain Insulin Analog and a polynucleotide sequence encoding the analog

Patent No: US 6,630,348 B1

October 7th 2003

 

 

CLAIM


COMPARISON WITH OUR SEQUENCE

Y/N

 

A single chain insulin analogue compound of formula (I) having the properties of greater insulin receptor binding activity than proinsulin and less insulin receptor binding activity than insulin:

B chain -  X – A chain wherein:

 

General B – X – A chain single chain formula

Y

 

B and A chain are human insulin chains, respectively and,

 

 

Our B and A chain are human insulin chains although our A chain includes a modification (additional glycine)

 

N

 

 

X is a joining peptide of about 5 to 18 amino acids comprising the following sequence: Gly-Gly-Gly-Pro-Gly- Lys-Arg

 

Where the term ‘comprising’ is included, the patent requires that the specific sequence named MUST be part of the linker region.

 

Although our sequence is 12 amino acids long, it does not contain the ‘GGGPGLR’ identified in the patent

 

N

LEE ET AL.

Single Chain Insulin Analogs

Patent No: EP 1 193 272 B1

October 30th 2004

 

 

CLAIM


COMPARISON WITH OUR SEQUENCE

Y/N

 

A single chain insulin analogue compound of formula (I) having the properties of greater insulin receptor binding activity than prosinsulin and less insulin receptor binding activity than insulin:

 

B Chain – UI – Zn – Y – ZI – Un – A chain

 

 

 

B and A chain are human insulin chains respectively and

 

 

We have a modified A chain

N

 

U is an arginine or lysine residue

 

Our ‘U’ is glutamine

N

 

Z is a glycine

 

 

Z Is Glycine

Y

 

 

I is an integer of 2 – n

N is an integer of 0 or 2 and

 

The maximum size of the linker sequence when considering this is 9 amino acids. Since our sequence is 12 amino acids they are outside the scope

 

N

 

Y is glycine-proline-glycine, or alanine-proline-glycine-aspartic acid–valine, or tyrosine-proline-glycine-aspartic acid-valine, or histidine-proline-glycine-aspartic acid-valine.

 

 

 

Our sequence has no proline

 

N
3rd patent shite
INSERT YOUR PATENT HERE


</body> </html>